Pharma’s Physician Bailout
The pharmaceutical industry has been very generous in making payments to physicians. Last year (2010), for example, a mere dozen pharmaceutical companies paid $760 million to physicians and other health care providers for consulting, speaking, research and expenses. On average, how much do you think that comes to for every physician in the U.S.?
Proposed Rules for Physician Payment Sunshine Act
Looming Challenges Cloud Implementation. This article reviews the strategic implications of the Sunshine Act and also presents highlights of the draft regulations rule released by the Centers for Medicare and Medicaid Services on December 15, 2011.
Pharma Marketing News Vol. 10, No. 17: 10 November 2011
Welcome to Volume 10, Issue #17 (10 NOVEMBER 2011) of Pharma Marketing News.
Pharma Marketing News Vol. 10, No. 18: 1 December 2011
Welcome to Volume 10, Issue #18 (1 DECEMBER 2011) of Pharma Marketing News.
Pharma Marketing News Vol. 10, No. 16: 27 October 2011
Welcome to Volume 10, Issue #16 (27 OCTOBER 2011) of Pharma Marketing News.
Pharma TeleWeb e-Detailing
This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.
Consequences of eDetailing Technology
The Death of the Traditional Pharma Salesman and the Birth of the 'Sales Cyborg.' eDetailing in one form or another seems to be making a comeback since the recession hit the drug industry in 2007 and 2008. Which is the 'chicken' and which is the 'egg'? Did the uptick in adoption of eDetailing technology lead to the recent layoff of pharma reps or were reps laid off because of the economy and subsequently replaced by machines?
Pharma Marketing News Vol. 10, No. 1: JANUARY 12, 2011
Welcome to Volume 10, Issue #1 (JANUARY 12, 2011) of Pharma Marketing News.
New Big Pharma Economies of Scale
How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?
The Pharmaguy Social Media Timeline&trade: A Record of Social Media Events Impacting the Pharmaceutical...
The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.
